Transcriptomic changes and immune modulation associated with antiparasitic treatment in chronic Trypanosoma cruzi infection.

dc.contributor.authorRos Lucas, Albert
dc.contributor.authorAlonso Padilla, Julio
dc.contributor.authorGabaldón Figueira, Juan Carlos
dc.contributor.authorMartínez-Peinado, Nieves
dc.contributor.authorLosada-Galván, I.
dc.contributor.authorPosada, Elizabeth
dc.contributor.authorEscabia, Elisa
dc.contributor.authorMartín Mur, Beatriz
dc.contributor.authorGut, Marta
dc.contributor.authorEsteve Codina, Anna
dc.contributor.authorGascón, Joaquim
dc.contributor.authorPinazo Delgado, Mª Jesus
dc.date.accessioned2026-01-30T12:46:41Z
dc.date.available2026-01-30T12:46:41Z
dc.date.issued2024
dc.date.updated2026-01-30T12:46:41Z
dc.description.abstractChagas disease is a neglected tropical infection that affects over 6 million people worldwide. This study explores transcriptomic changes in <em>T. cruzi</em>-infected subjects before and after receiving treatment. Using total RNA sequencing, gene transcription was analyzed in peripheral blood mononuclear cells from asymptomatic (n=19) and symptomatic (n=8) <em>T. cruzi</em>-infected individuals, and from non-infected controls (n=15). Differential expression was compared across groups and before/after treatment in <em>T. cruzi</em>-infected subgroups. Transcriptomic changes associated with untreated infection were observed in comparisons with controls, with 12 upregulated and 206 downregulated genes in all the subjects infected with <em>T. cruzi</em>, and 47 upregulated and 215 downregulated genes in the symptomatic group. Very few differentially expressed genes were found after treatment and between the different infected groups. A gene set enrichment analysis highlighted several immune-related pathways activated during the infection, with antiparasitic therapy normalizing immune function after treatment. This matched changes in the kynurenine/tryptophan ratio, increased in pre-treatment samples and suggesting chronic immune fatigue, which was restored following treatment. The described differentially expressed genes can provide insights for the study of new potential biomarkers and pathways associated with disease progression and treatment response.
dc.format.extent29 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec757854
dc.identifier.issn0022-1899
dc.identifier.urihttps://hdl.handle.net/2445/226484
dc.language.isoeng
dc.publisherOxford University Press
dc.relation.isformatofVersió postprint del document publicat a: https://doi.org/10.1093/infdis/jiae429
dc.relation.ispartofJournal of Infectious Diseases, 2024
dc.relation.urihttps://doi.org/10.1093/infdis/jiae429
dc.rights(c) Ros-Lucas, A. et al., 2024
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.subject.classificationTripanosoma
dc.subject.classificationMalaltia de Chagas
dc.subject.classificationImmunitat
dc.subject.otherTrypanosoma
dc.subject.otherChagas' disease
dc.subject.otherImmunity
dc.titleTranscriptomic changes and immune modulation associated with antiparasitic treatment in chronic Trypanosoma cruzi infection.
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/acceptedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
891700.pdf
Mida:
1.21 MB
Format:
Adobe Portable Document Format